RxDoctor Payments Data

Bradford Matthews, MD

Orthopaedic Surgery · Ft Wainwright, AKNPI 1063523959

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (40.7%), education and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Zimmer Biomet at 50.3% of the total. Reporting peaked in 2020 at $4,341 and has fallen 89.4% since, to $458 in 2025.

$10,128in general payments, 2019–2025

Across 92 payments — averaging $110.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$5K
  • Arthrex$4K
  • Active Medical, LLC$1K
  • Vericel Corporation$169
  • Johnson & Johnson$58
  • Smith+Nephew$29

What the payments were for

  • Travel & lodging$4,12441%
  • Food & beverage$2,52025%
  • Education$3,46834%
  • Entertainment$160%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Zimmer Biomet70$5,091
Arthrex7$3,500
Active Medical, LLC5$1,280
Vericel Corporation7$169
Johnson & Johnson2$58
Smith+Nephew1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,128 in reported general payments places this provider in the 80th percentile of 63 orthopaedic surgery providers in Alaska.

See all orthopaedic surgery providers in Alaska

Medicare billing

Part B allowed, 2024
$23,880
Medicare patients
56
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib11$366
Meloxicam47$132

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Ft Wainwright

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →